Twitter Facebook LinkedIn YouTube

Pascal Biosciences (TSXV:PAS) Announced a non-brokered Private Placement

Video Platform Video Management Video Solutions Video Player

The company is looking to raise gross proceeds of up to $1 million from the placement of up to 5 million units priced at $0.20 per unit. The units consist of 1 share and 1 warrant, with each warrant exercisable at $0.35 for 12 months, subject to an acceleration clause.

Additional Information:

Company: Pascal Biosciences
Website: http://www.pascalbiosciences.com
Stock Symbol: TSXV:PAS
Transcript: Available

Video Transcript:

I’m Megan Edwards for Investmentpitch Media

Pascal Biosciences, a biotechnology company, has announced a non-brokered private placement.

The company is looking to raise gross proceeds of up to $1 million from the placement of up to 5 million units priced at $0.20 per unit.

The units consist of 1 share and 1 warrant, with each warrant exercisable at $0.35 for 12 months, subject to an acceleration clause.

Proceeds will be added to working capital.

The shares are currently trading at $0.15.

Pascal is targeting innovative therapies for serious diseases, including COVID-19.

Pascal is also developing treatments for cancer with targeted therapies for acute lymphoblastic leukemia and cannabinoid-based therapeutics.

Pascal's leading portfolio also comprises a small molecule therapeutic, PAS-403, that is advancing into clinical trials for the treatment of glioblastoma, and PAS-393, an immuno-stimulatory cannabinoid to be used in combination with checkpoint inhibitor therapy.

For more information, please visit the company’s website at www.pascalbiosciences.com, contact Dr. Patrick W. Gray, CEO, by email at invest@pascalbiosciences.com.

I’m Megan Edwards for Investmentpitch Media